Boehringer Ingelheim and GoodRx Partner to Enhance Humira Biosimilar Access

GoodRx has entered into a partnership with the pharmaceutical company Boehringer Ingelheim to make a biosimilar for Humira, known as adalimumab, accessible at a more affordable price. The drugmaker will provide citrate-free adalimumab-adbm at a cash price exclusively available on GoodRx. This initiative ensures that anyone with a prescription can acquire the medication at one of 70,000 pharmacies across the country, regardless of whether they have insurance.

Starting from July 18, Boehringer Ingelheim and GoodRx will offer the drug in both high-concentration and low-concentration versions, available in auto-injectors or pre-filled syringes. The cost will be set at $550 for a two-pack. The companies highlighted that this pricing represents a 92% reduction compared to the cost of a Humira prescription.

Dorothy Gemmell, the Chief Commercial Officer at GoodRx, commented on the partnership in a press release, noting the company's decade-long effort to lower medication costs for patients. She emphasized the importance of making biosimilars affordable and accessible, and expressed enthusiasm for using GoodRx's extensive platform to bridge this gap and enhance accessibility to Adalimumab-adbm.

The Food and Drug Administration has approved Adalimumab-adbm for interchangeable use with Humira. Biosimilars like Adalimumab-adbm are considered vital in reducing the cost of high-priced brand-name drugs, with Humira being a prominent example that biosimilar competitors have targeted. Despite the potential benefits, the adoption of biosimilars has been relatively slow.

In response, several major pharmacy benefit managers have introduced programs to facilitate easier access to these products. Chris Marsh, Senior Vice President of Value and Access at Boehringer Ingelheim, pointed out that patients with chronic inflammatory diseases often struggle to afford essential biologic medicines, including biosimilars, especially if they are uninsured or underinsured. He stated that the collaboration with GoodRx to offer Adalimumab-adbm at a reduced price aims to lower financial barriers and improve access to essential treatments.